RINOFED PLUS price in UAE

Overview

Welcome to Dwaey, specifically on RINOFED PLUS Syrup page.
This medicine contains an important and useful components, as it consists of Pseudoephedrine HCl, Triprolidine HCl, Paracetamol.
RINOFED PLUS is available in the market in concentration 25mg, 1.25mg, 125mg/5ml and in the form of Syrup.

JAZEERA PHARMACEUTICAL INDUSTRIES is the producer of RINOFED PLUS and it is imported from SAUDI ARABIA, The most popular alternatives of RINOFED PLUS are listed downward .

Mode Of Action

Triprolidine is a potent competitive histamine H1-receptor antagonist with mild sedating and antimuscarinic properties. Pseudoephedrine, an alpha- and beta-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of alpha-adrenergic receptors of the respiratory mucosa. Dextromethorphan is a centrally acting cough suppressant which acts on the cough centre in the medulla.

Indication

Flu
Colds
Runny nose
Dry coughs
Non-productive cough
Nasal congestion

Precaution

3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.

Side Effects

Dizziness
GI disturbances.

Contra indication

Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol. Potentially Fatal: Memantine, moclobemide. Triprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine. Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.